ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Tennessee » Hematology Oncology

Top Hematology Oncology Prescribers in Tennessee

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CURTIS OWENS M.D.

Hematology Oncology

5,483

$531K

256
153 are 65+

8%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 14%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$97
Average prescription price

Avg: $424

WILLIAM KINCAID M.D.

Hematology Oncology

4,058

$903K

435
299 are 65+

23%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 19%

$222
Average prescription price

Avg: $424

WILLIAM REID MD

Hematology Oncology

3,994

$149K

136
86 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

23%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$37
Average prescription price

Avg: $424

THOMAS RATLIFF MD

Hematology Oncology

3,582

$1.21M

311
217 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

21%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$339
Average prescription price

Avg: $424

SYLVIA KRUEGER MD

Hematology Oncology

3,514

$2.21M

378
284 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

28%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$628
Average prescription price

Avg: $424

KIRBY SMITH MD

Hematology Oncology

2,917

$819K

246
194 are 65+

11%
patients receiving schedule two controlled substances

Avg: 16%

20%
patients receiving schedule three controlled substances

Avg: 14%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$281
Average prescription price

Avg: $424

SUDARSHAN DODDABELE MD

Hematology Oncology

2,849

$624K

429
376 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

10%
prescriptions for brand name drugs

Avg: 19%

$219
Average prescription price

Avg: $424

DEREK HOLLAND M.D.

Hematology Oncology

2,789

$1.03M

319
244 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

16%
patients receiving schedule three controlled substances

Avg: 14%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 19%

$369
Average prescription price

Avg: $424

DONALD GRAVENOR M.D.

Hematology Oncology

2,613

$1.22M

210
141 are 65+

27%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$466
Average prescription price

Avg: $424

WILLIAM WALSH M.D.

Hematology Oncology

2,554

$1.23M

286
218 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 19%

$483
Average prescription price

Avg: $424

DAVEY DANIEL MD

Hematology Oncology

2,436

$863K

322
255 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

15%
patients receiving schedule three controlled substances

Avg: 14%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$354
Average prescription price

Avg: $424

FURHAN YUNUS MD

Hematology Oncology

2,399

$1.04M

284
184 are 65+

25%
patients receiving schedule two controlled substances

Avg: 16%

26%
patients receiving schedule three controlled substances

Avg: 14%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 19%

$435
Average prescription price

Avg: $424

JARVIS REED MD

Hematology Oncology

2,219

$1.66M

265
165 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

23%
patients receiving schedule three controlled substances

Avg: 14%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

33%
prescriptions for brand name drugs

Avg: 19%

$748
Average prescription price

Avg: $424

CHARLES FAMOYIN M.D.

Hematology Oncology

2,108

$985K

347
178 are 65+

35%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 19%

$467
Average prescription price

Avg: $424

HESAMM GHARAVI MD

Hematology Oncology

2,070

$1.05M

223
172 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$508
Average prescription price

Avg: $424

LEE SCHWARTZBERG MD

Hematology Oncology

1,879

$1.01M

230
183 are 65+

5%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$539
Average prescription price

Avg: $424

BRIAN WALKER DO

Hematology Oncology

1,876

$707K

316
240 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

20%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 19%

$377
Average prescription price

Avg: $424

PATRICIA ADAMS-GRAVES MD

Hematology Oncology

1,869

$810K

136
11 are 65+

54%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 19%

$434
Average prescription price

Avg: $424

BRADLEY SOMER MD

Hematology Oncology

1,832

$683K

250
192 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

8%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$373
Average prescription price

Avg: $424

ARNEL PALLERA MD

Hematology Oncology

1,805

$956K

219
169 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

16%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$530
Average prescription price

Avg: $424

RICHARD GRAPSKI MD

Hematology Oncology

1,796

$863K

273
200 are 65+

20%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$480
Average prescription price

Avg: $424

ARCHIE WRIGHT DO

Hematology Oncology

1,766

$1.02M

296
205 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 19%

$576
Average prescription price

Avg: $424

DARRELL JOHNSON MD

Hematology Oncology

1,723

$808K

274
220 are 65+

17%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$469
Average prescription price

Avg: $424

CLYDE JONES M.D.

Hematology Oncology

1,688

$1.48M

257
202 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

30%
prescriptions for brand name drugs

Avg: 19%

$878
Average prescription price

Avg: $424

MITCHELL MARTIN MD

Hematology Oncology

1,678

$1.27M

226
182 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$759
Average prescription price

Avg: $424

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank